RxDoctor Payments Data
★ My doctorsLook up a doctor →

Jason Luke, MD

Hematology & Oncology · Pittsburgh, PANPI 1093989196

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $227,586 of the $300,398 with a category attached, or 75.8%. 33 manufacturers reported payments, led by Merck at 26.3% of the total. Reporting peaked in 2019 at $62,051 and has fallen 87.2% since, to $7,923 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$300,398in general payments, 2019–2025

Across 248 payments — averaging $1211.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$79K
  • E.r. Squibb & Sons, L.L.C.$26K
  • Servier Pharmaceuticals LLC$22K
  • Regeneron$20K
  • Novartis$20K
  • Bayer$19K
  • plus $115K from 27 others
$14,725,116in research payments, 2019–2025

Across 936 payments — averaging $15,732 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$5.5M
  • Takeda Pharmaceuticals U.S.A., Inc.$1.3M
  • AbbVie$1.1M
  • Pfizer$802K
  • Novartis$756K
  • Sanofi US Services Inc.$730K
  • plus $4.6M from 18 others

What the payments were for

  • Consulting fees$227,58676%
  • Speaking & faculty fees$24,6058%
  • Travel & lodging$43,82715%
  • Food & beverage$4,2871%
  • Gifts$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck74$79,154
E.r. Squibb & Sons, L.L.C.31$25,720
Servier Pharmaceuticals LLC3$21,852
Regeneron19$20,234
Novartis13$19,605
Bayer13$19,258
Teva Pharmaceuticals USA, Inc.3$19,000
EMD Serono, Inc.12$15,377
Janssen Global Services, LLC5$14,992
Regeneron Healthcare Solutions, Inc.21$9,321
Array Biopharma Inc4$7,425
Incyte Corporation11$5,904
Genmab U.S., Inc.4$5,880
Eisai Inc.3$5,605
Astrazeneca UK Limited6$5,544
Krystal Biotech Inc3$4,030
AbbVie2$3,544
G1 Therapeutics, Inc.1$2,480
Genentech, Inc.1$2,310
Servier Bioinnovation1$2,170
Shionogi Inc2$2,040
Alnylam Pharmaceuticals Inc.1$1,755
Novartis Pharma AG1$1,550
Tesaro, Inc.2$1,382
Kadmon Corporation LLC1$1,200
Pfizer1$938
Partner Therapeutics, Inc.1$620
Boehringer Ingelheim2$491
Modernatx, Inc.2$469
F. Hoffmann-la Roche AG1$319
AstraZeneca1$95
Reflexion Medical, Inc.2$93
Genentech USA, Inc.1$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300,398 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$23,361
Medicare patients
92
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pittsburgh

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →